NEW YORK — (BUSINESS WIRE) — Cytovia, the oncology subsidiary of Immune Pharmaceuticals (IMNP) (“Immune” or the “Company”), a clinical stage biopharmaceutical company, today announced the publication of new results supporting the benefits of its lead compound Ceplene® (histamine dihydrochloride). In parallel, Cytovia has filed a world-wide patent to protect the use of Ceplene® in CML. In the British Journal of Haematology new publication (, the authors show that the genetic elimination of NOX2 function delayed the development of CML in mice and prolonged survival. These results support that Ceplene®, or other inhibitors of NOX2 function, may be efficacious in CML.